F. Misselwitz

Publications118
h-index35
Citations12,498
Highly Influential Citations460
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • G. Lip
  • 2,322 Publications • 112,746 Citations
  • A. Kakkar
  • 285 Publications • 21,252 Citations
  • A. Turpie
  • 430 Publications • 41,416 Citations
  • S. Goto
  • 324 Publications • 15,816 Citations
  • Publications
  • Influence
Oral rivaroxaban for symptomatic venous thromboembolism.
BACKGROUND Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need for… Expand
  • 1,981
  • 66
  • PDF
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
BACKGROUND This phase 3 trial compared the efficacy and safety of rivaroxaban, an oral direct inhibitor of factor Xa, with those of enoxaparin for extended thromboprophylaxis in patients undergoing… Expand
  • 1,305
  • 51
  • PDF
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
BACKGROUND We investigated the efficacy of rivaroxaban, an orally active direct factor Xa inhibitor, in preventing venous thrombosis after total knee arthroplasty. METHODS In this randomized,… Expand
  • 1,242
  • 45
  • PDF
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
BACKGROUND We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. METHODS In this double‐blind… Expand
  • 904
  • 41
  • PDF
Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention.
BACKGROUND AND OBJECTIVE Rivaroxaban is an oral, direct Factor Xa inhibitor, which is at an advanced stage of clinical development for prevention and treatment of thromboembolic disorders. Two phase… Expand
  • 197
  • 26
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
BACKGROUND A fixed-dose regimen of rivaroxaban, an oral factor Xa inhibitor, has been shown to be as effective as standard anticoagulant therapy for the treatment of deep-vein thrombosis, without the… Expand
  • 1,581
  • 16
  • PDF
Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry
Background Limited data are available on the characteristics, clinical management, and outcomes of patients with atrial fibrillation at risk of stroke, from a worldwide perspective. The aim of this… Expand
  • 346
  • 16
  • PDF
Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute…
Background— An effective and safe oral anticoagulant that needs no monitoring for dose adjustment is urgently needed for the treatment of diseases that require long-term anticoagulation. Rivaroxaban… Expand
  • 332
  • 14
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT…
We performed a randomized dose-ranging study, double-blind for rivaroxaban doses and open-label for the comparator (low-molecular-weight heparin followed by vitamin K antagonists) to assess the… Expand
  • 313
  • 14
Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement.
Rivaroxaban (Xarelto) is an oral, direct factor Xa inhibitor in advanced clinical development for the prevention and treatment of thromboembolic disorders. The aim was to compare the population… Expand
  • 246
  • 11
...
1
2
3
4
5
...